Yahoo Web Search

  1. Yahoo Finance Results

  2. This could indicate that investors who seek to profit from falling equity prices are not currently targeting PFE. Index (PMI) data, output in the Healthcare sector is rising.

  3. Better Buy: Pfizer Inc. vs. Johnson & Johnson

    Motley Fool via Yahoo FinanceDec 01 13:42 PM

    With only one month remaining in 2017, it's pretty clear which big pharma stock has been the better pick this year between Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ). J&J's ...

    37.20+0.74 (+2.03%)

    at Fri, Dec 15, 2017, 4:00PM EST - U.S. Markets closed

    After Hours 37.20 N/A (N/A%)

    Delayed Quote

    • Open 36.78
    • High 37.22
    • Low 36.71
    • Prev. Close 36.46
    • 52 Wk. High 37.22
    • 52 Wk. Low 30.90
    • P/E 22.98
    • Mkt. Cap 221.74B
  4. Pfizer Inc. (PFE) (“Pfizer”) today announced that it has commenced a private offer to exchange (the “Exchange Offer”) any and all of its outstanding £1,500,000,000 6.500 ...

  5. Pfizer/Merck KGaA's Bavencio Fails in Gastric Cancer Study

    Zacks via Yahoo FinanceNov 29 16:11 PM

    Pfizer, Inc. PFE and its Germany-based partner Merck KGaA MKGAF announced that a phase III study evaluating their key pipeline candidate, avelumab, for the treatment of gastric ...

  6. GlaxoSmithKline GSK along with partner Pfizer, Inc. PFE announced that its HIV-focused company, ViiV Healthcare, has initiated a phase III program to evaluate combination of long-acting ...

  7. Cancer Space Update: Pfizer's Bavencio Fails in Phase III

    Zacks via Yahoo FinanceDec 01 14:33 PM

    There was no major news in the cancer space this week, except the failure of Pfizer Inc. s PFE Bavencio in a gastric cancer study. In a setback to Eisai Co., Ltd. ESALY, National ...

  8. Pfizer Inc. PFE announced that it has bought exclusive rights to develop and commercialize Swiss company Basilea Pharmaceutica’s anti-fungal treatment, Cresemba (isavuconazole) ...

  9. Block, who has taught mergers & acquisitions at the school, has advised clients on numerous precedent-setting transactions, including Pfizer Inc.'s $68 billion acquisition of Wyeth—the ...

  10. Pfizer Inc. PFE announced encouraging new data of a post-hoc analysis from a phase III study, evaluating the combination of its breast cancer drug, Ibrance (palbociclib), with ...

  11. Glaxo Stock Down So Far This Year: Is a Reversal in Store?

    Zacks via Yahoo FinanceNov 30 14:19 PM

    On the call, Glaxo expressed its interest to purchase Pfizer’s PFE consumer healthcare business, which the latter plans to put up for sale. Since the earnings release, shares of Glaxo ...

  1. Ads
    related to PFIZER, INC